THE Therapeutic Goods Administration has launched a consultation into the Orphan Drug Program, looking at whether it is still fulfilling its intended purpose: to provide an incentive to sponsors to bring medicines for a small population to market.
"Since the inception of the TGA Orphan Drug Program there have been developments in the definition and recognition of 'rare diseases,'" an overview reads, including improvements in technology to diagnose rare diseases and to tailor therapies.
The industry is invited to make comment on the consultation, with a deadline of 25 Nov 2016 after which feedback will be released.
More details at www.tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 16
